c-myc, N-myc and L-myc are the three members of the myc oncoprotein family whose role in the pathogenesis of many human neoplastic diseases has received wide empirical support. In this review, we ®rst summarize data, derived mainly from non-clinical studies, indicating that these oncoproteins actually serve quite dierent roles in vivo. This concept necessarily lies at the heart of the basis for the observation that the deregulated expression of each MYC gene is reproducibly associated with only certain naturally occurring malignancies in humans and that these genes are not interchangeable with respect to their aberrant functional consequences. We also review evidence implicating each of the above MYC genes in speci®c neoplastic diseases and have attempted to identify unresolved questions which deserve further basic or clinical investigation. We have made every attempt to review those diseases for which signi®cant and con®rmatory evidence, based on studies with primary tumor material, exists to implicate MYC members in their causation and/or progression.
It has been known for some time that c-myc, N-myc and L-myc are expressed in distinct patterns during embryogenesis (Zimmerman et al., 1986; Zimmerman and Alt, 1990) . c-myc tends to be highly expressed in most rapidly proliferating cells and is generally low to absent during quiescence. N-myc, although present at low levels in many neonatal tissues, is expressed at highest levels in pre-B cells, kidney, forebrain, hindbrain and intestine. In some tissues such as the retina, telencephalon, and intestine, N-myc expression has been shown to persist during dierentiation whereas c-myc is down-regulated (Mugrauer et al., 1988; Hirning et al., 1991) . During gastrulation, c-myc is expressed most abundantly in extraembryonic tissues, whereas N-myc is most abundant in the expanding primitive streak and other regions of the embryonic mesoderm. N-myc is also down-regulated during the dierentiation of this latter tissue to epithelium (Downs et al., 1989) . L-myc is expressed in the developing kidney, as well as in the newborn lung and in both proliferative and dierentiative compartments of the brain and neural tube (Hatton et al., 1996) . Xu et al. (1991) have found that both transcriptional initiation and attenuation (Bentley and Groudine, 1986 ) play important roles in regulation of each MYC gene and that these controls operate in distinct ways. For example, in the postnatal developing brain, attenuation was the main mechanism by which N-myc mRNA levels were modulated whereas L-myc mRNA levels appeared to be regulated primarily through transcriptional initiation.
Dierential eects of myc proteins on DNA binding, transcriptional activation and transformation
When expressed in recombinant form, all myc proteins bind to the core E-box element CA T / C GTG (Blackwell et al., 1990 Prochownik and VanAntwerp, 1993) . However, subtle preferences, particularly for¯anking sequences, have been noted (Prendergast and Zi, 1991; Barrett et al., 1992; Fisher et al., 1993; Ma et al., 1993; Prochownik and VanAntwerp, 1993) . Because very few in situ DNA binding sites for any of these proteins have been characterized (Grandori et al., 1996) and because the E-boxes of acknowledged cmyc transcriptional targets have not been examined for binding by N-myc and L-myc, it is not yet completely clear how in vitro binding site preferences might be related to those favored in vivo. Recent results have shown that L-myc is incapable of activating the ornithine decarboxylase (ODC) promoter (HL Zhang and EVP, unpublished observations), a generally accepted c-myc-responsive target (Bello-Fernandez et al., 1993) . This could be explained by preferential DNA binding, by dierential requirements for transcriptional co-activators, or by dierences in strengths of the myc protein transcriptional activation domains (TADs) (Barrett et al., 1992) .
Early studies established that N-myc and c-myc were equally potent in transforming primary embryonic rat ®broblasts in vitro in collaboration with an activated ras oncogene Yancopoulos et al., 1985) . In contrast, L-myc is only 1 ± 10% as eective (Birrer, 1988) . It was originally proposed that this was due to L-myc possessing a weaker TAD than either cmyc or N-myc (Barrett et al., 1992) . However, it is now known that the so-called`Myc Box II' domain of cmyc is required for transformation but not for transactivation (Li et al., 1994; Brough et al., 1995; MacGregor et al., 1996) . It would therefore appear that dierences in TAD strength are not directly responsible for the dierences in cooperativity with ras. In addition, the studies of Barrett et al. (1992) were performed in Rat1a ®broblasts which do not require a cooperating ras oncogene to attain a transformed state. Thus, a direct comparison to primary embryo ®broblasts transformed by myc+ras is dicult.
Eects of MYC gene gain-and loss-of-function in vivo
A number of c-myc-activated or repressed genes have now been described (reviewed by Dang, 1999) . Recent results, however, indicate that the regulation of these genes by c-myc overexpression diers among cell types, strongly suggesting an important role for tissue-speci®c co-activators or other factors (Ben-Yosef et al., 1998) . The statement that dierences in target gene expression pro®les between cell lines overexpressing two dierent myc genes are due to intrinsic dierences in the myc proteins themselves is therefore complicated by this consideration (Ben-Yosef et al., 1998) . We have recently compared the properties of three cell lines engineered to express c-myc, N-myc, or L-myc at equivalent levels (Nesbit et al., 1998) . All three, along with a vector control, were derived from the same parental cell line which expresses endogenous c-myc but neither N-myc nor L-myc. Signi®cant dierences were observed in the abilities of the three oncoproteins to modulate apoptosis in response to obligate cytokine withdrawal and/or to treatment with cytotoxic drugs, as well as in the abilities of Bcl-2 and Bcl-X L to rescue the apoptotic phenotype. The indirect evidence provided by these experiments suggests that, within the same cellular context, each of the three myc oncoproteins modulates distinct, albeit likely overlapping, sets of target genes.
The classic experiment of Adams et al. (1985) showed that transgenic mice, expressing a c-myc gene under the control of immunoglobulin (Ig) m or k enhancer elements, develop monoclonal or oligoclonal early pre-B cell lymphoid malignancies. This provided an important in vivo context within which to compare N-myc and L-myc. Rosenbaum et al. (1989) , Dildrop et al. (1989) and Sheppard et al. (1998) thus created Em-N-myc transgenic animals and showed that they too develop clonal lymphoid tumors of pre-B and Bcell origin. In the latter case, the disease resembled human follicular lymphoma and followed a more indolent course which may have been attributable to lower levels of transgene expression and/or strain dierences. Of particular interest in the latter case were studies performed in newborns infected with Moloney murine leukemia virus. Like their Em-c-myc counterparts, these mice manifested a higher incidence of disease with reduced latency. However the retroviral insertion sites in lymphomas were dierent in the two groups. These studies suggested that, although aberrant expression of either myc protein can lead to lymphomagenesis, the pathways which cooperate in this process are quite distinct.
In contrast to the above studies with c-myc and Nmyc, Em-L-myc transgenic mice express L-myc preferentially in T cells and succumb to T-cell lymphomas (Moroy et al., 1991) . Cross-breeding with animals transgenic for Em-pim-1, a gene known to cooperate with c-myc in murine lymphomagenesis (van Lohuizen et al., 1989) , led to an acceleration of disease onset. Nonetheless, the predilection toward the development of T cell neoplasia was maintained. A comparison of doubly transgenic animals revealed that c-myc/pim-1 animals developed lymphomas prenatally, whereas Nmyc/pim-1 and L-myc/pim-1 animals developed lymphomas with a mean latency of 36 and 94 days, respectively.
One additional study (Morgenbesser et al., 1995) has examined the eects of enforced transgene expression in the developing lens. During the process of lens maturation, growth arrest and dierentiation of epithelial cells into lens ®bers are associated with decreases in endogenous c-myc and L-myc. c-myc transgene expression, under the control of an alphaAcrystallin promoter, led to relatively normal lens ®ber dierentiation in spite of an abnormal degree of inappropriate cell cycle progression. Enforced L-myc expression was associated with severe disorganization of the lens ®ber compartment and an inhibition of latestage dierentiation in the face of normal withdrawal from the cell cycle. It was concluded that the two proteins were participating in distinct processes within the same cell type.
Studies with targeted disruption of each of the myc loci have provided additional evidence in favor of dierential function of their encoded proteins. Homozygous c-myc knockout animals die at embryonic day 9.5 ± 10.5 with abnormalities of the heart, pericardium, neural tube, and a delay or failure in embryonic turning . Homozygous N-myc knockout animals survive about 1 ± 2 days longer than their c-myc knockout counterparts and show developmental defects in many of the tissues that normally express N-myc (mesonephros, gut, lung and central and peripheral nervous systems) (Stanton et al., 1992) . A more recent study in N-myc knockout mice (Giroux and Charron, 1998) has demonstrated extensive hepatic apoptosis in day 11.5 embryos and a reduction in the number of liver-derived hematopoietic cells. Whether this represents an intrinsic hematopoietic cell defect or an environmental one remains to be established. A partial N-myc knockout that allows for fetal survival has also been described (Moens et al., 1992) . Neonatal animals, however, still succumb as a result of lung epithelial hypoplasia, without signi®cant abnormalities in other N-myc expressing tissues. These studies indicate that the developing lung is particularly sensitive to N-myc.
Finally, an exhaustive study performed in homozygous L-myc knockout animals (Hatton et al., 1996) , failed to reveal any phenotype, even in tissues which normally express the highest levels of L-myc.
In summary, most evidence to date favors the idea that the three myc genes share common properties but are not entirely redundant.
c-myc and human disease

Burkitt's lymphoma (BL)
Numerous studies have established that virtually every case of BL involves the juxtaposition of C-MYC located on chromosome 8 with regulatory elements of the immunoglobulin m heavy chain or l and k light chains located on chromosomes 14, 22, or 2, respectively (reviewed in Spencer and Groudine, 1991). As noted above, the experiments of Adams et al. (1985) , demonstrating the development of pre-B cell and B cell lymphomas in Em-c-myc transgenic animals, contributed signi®cantly to the now widely accepted concept that C-MYC deregulation is an essential aspect of BL pathogenesis. Just as important was the subsequent ®nding (Langdon et al., 1986 ) that young Em-c-myc transgenic animals possess an expanded, polyclonal pool of actively proliferating pre-B cells with a concurrent reduction in the number of mature B cells. With time, these animals developed the clonal malignancies described in the original report. These ®ndings represented some of the ®rst solid in vivo experimental support for the`multi-hit' concept of cancer that is favored today (Lengauer et al., 1998) . As discussed below, recent ®ndings in BL only strengthen this model.
In addition to rearrangements of C-MYC, other nonrandom somatic mutations within its second exon have been observed (Rabbitts et al., 1983; Johnston and Carrol, 1992; Bhatia et al., 1993 Bhatia et al., , 1995 Yano et al., 1992; Albert et al., 1994) . These changes tend to involve Thr 58 , Ser 62 , or neighboring residues. Thr 58 and Ser 62 are major sites of c-myc phosphorylation and their mutation has been reported to severely inhibit transactivation of a c-myc target gene Seth et al., 1993) . Others, however, have not observed such an eect (Henriksson et al., 1993; Lutterbach and Hann, 1994) . Under conditions that may be more physiological, we have stably expressed a double Thr 58 /Ser 62 ?Ala c-myc mutant and measured levels of ornithine decarboxylase (ODC), an enzyme whose gene is generally accepted as being c-myc inducible (Bello-Fernandez et al., 1993) . We have observed that this mutant cannot up-regulate endogenous ODC enzyme activity whereas wild-type c-myc does so by fourfold (CEN and EVP, unpublished) .
Despite the unresolved controversy surrounding the roles of Thr 58 and Ser 62 in transactivation, most investigators are in agreement that both engineered and BL-derived mutations of these regions possess increased transforming activity (Henriksson et al., 1993; Pulverer et al., 1994; Hoang et al., 1995) . This appears to be accomplished without any alteration in the rate of c-myc-induced apoptosis (Hoang et al., 1995) .
One potential mechanism to explain the increased transforming activity of BL-derived c-myc mutant proteins has been provided by Beijersbergen et al. (1994) and Gu et al. (1994) . They showed that the transactivation and transformation functions of wildtype c-myc are normally subject to down-regulation by the pRB-related protein p107 as the result of a direct physical interaction between the two proteins. In contrast, many of the c-myc mutants from BL tumors have lost the ability to be down-regulated by p107, although association between the two proteins still occurs (Hoang et al., 1995) . A more recent study, however, indicated that loss of p107-mediated negative regulation of c-myc transactivation is not an inevitable result of c-myc mutation (Smith-Sorenson et al., 1996) . Unfortunately, the eects of these mutations on transformation were not examined. Since transactivation and transformation functions of c-myc are separable genetic functions, the model most compatible with the above data is that somatic mutations of c-myc result in proteins whose transforming activity cannot be negatively regulated by p107. These mutations may also up-regulate the transactivation function of c-myc and thus possibly augment transformation. It is noteworthy that the study by Smith-Sorenson et al. (1996) utilized mutants with only single missense mutations, whereas earlier studies utilized mutants with multiple missense mutations. Perhaps the former set of mutants allow for a greater discrimination by p107 and thus for a more selective eect on transformation.
In addition to the above-described mutations which alter the c-myc protein, others have been described in the non-coding ®rst exon of BL-derived c-myc alleles (Cesarman et al., 1987; Szanjert et al., 1987) . These mutations tend to cluster at the 3' end of the exon and the 5' end of the ®rst intron. They are associated with a loss of transcriptional attenuation that is believed to play a major role in regulating c-myc mRNA levels in response to environmental cues (Bentley and Groudine, 1986) .
Finally, at least one report has noted that aberrant c-myc transcripts have a much longer half life than wild-type transcripts. However, the actual alterations which are responsible for this phenomenon were not identi®ed (Eick et al., 1985) .
In summary, it is likely that somatic mutations in rearranged c-myc genes in BL contribute signi®cantly to the phenotype and/or progression of the disease. Those that alter the c-myc coding region might be particularly susceptible to altered regulation by p107. Perhaps the most direct way to examine these issues will be to generate transgenic strains which express the various BL-derived mutants. Such animals might be expected to develop a more rapid onset of lymphoma. A further prediction is that cross-bred animals which harbor both a wild-type Ig-c-myc transgene and a homozygous p107 deletion (LeCouter et al., 1998) would show accelerted lymphomagenesis at a rate which mirrored that seen in animals with mutant c-myc transgenes. Important clinical questions include whether translocated c-myc alleles acquire an increasing number of somatic mutations during disease progression and whether particular types of somatic mutations are predictive of clinical course. It is likely that high level, deregulated expression of C-MYC exists in intimate association with other mutations which contribute to BL initiation and/or progression. Perhaps the most widely studied protein in this regard is the p53 tumor suppressor. It is evident from the studies of several groups that approximately one-third of untreated BL tumors have co-existing p53 mutations (Gaidano et al., 1991; Ichikawa et al., 1993; Nomdedeu et al., 1997) . Furthermore, the fact that TSP53 is a c-myc target gene might contribute signi®cantly to the elevated levels of mutant p53 protein found in many BL tumors (Balint and Reisman, 1996 and references therein). Indeed the studies cited above may actually underestimate the frequency with which functional inactivation of p53 occurs in BL. Recent work performed in cell lines (Capoulade et al., 1998) has provided evidence for overexpression of mdm2, a protein which is a known inhibitor of p53 function (Piette et al., 1997) . This observation clearly deserves further investigation in primary tumors.
The consequences of p53 mutations in BL have recently been tested experimentally. Cherney et al. (1997) have shown that inactivation of wild-type p53 in a BL cell line increased its tumorigenicity in athymic mice. Conversely, restoration of wild-type p53 in a p53 mutant cell line reduced tumorigenicity. One obvious prediction of these experiments that has yet to be tested directly is that crosses between animals harboring an Ig-c-myc transgene and those nullizygous for p53 would produce progeny having a more rapid onset of lymphoma. These tumors might also be multi-clonal and manifest more aggressive behavior.
Burkitt's-like lymphomas (BLLs) are commonly encountered in patients with the acquired immunode®ciency syndrome (AIDS). Although the incidence of cmyc gene rearrangements into Ig loci is extremely high in BLL (Knowles, 1996 (Knowles, , 1997 Gaidano et al., 1998) , it is not invariably associated with the disease as it is in the case of true endemic BL . Other features that distinguish the two lymphoma types have been recently discussed . Despite these dierences however, the mechanisms involved in disease initiation and progression appear to be quite similar. For example C-MYC coding region mutations, and p53 inactivating mutations, similar to those seen in BL, have been described in a large percentage of BLLs Clark et al., 1994; Martin et al., 1998 and references therein).
Non-Burkitt's lymphoma
Low-grade follicular lymphomas are usually associated with Ig-Bcl-2 gene rearrangement (Tsujimoto et al., 1984; Ngan et al., 1988; Yano et al., 1992) and rarely involve c-myc locus translocations (Yano et al., 1992) . Over time, approximately 60 ± 80% of these lymphomas will undergo transformation to a more aggressive form. In a number of these lymphomas, all of which retain the original Ig-Bcl-2 abnormality, Ig-c-myc rearrangements can now be detected (Gauwerky et al., 1988; Lee et al., 1989; Yano et al., 1992) . These ®ndings are consistent with the known complementation between c-myc and Bcl-2 in transgenic systems where Bcl-2 is believed to protect against the proapoptotic tendencies of c-myc and thus allow for a more robust proliferative signal (Strasser et al., 1990; Marin et al., 1995 and references therein) .
Diuse large B-cell lymphomas (DLBLs) are a molecularly heterogeneous group of disorders that may originate de novo or evolve from follicular lymphomas. Approximately 50% of these tumors involve Ig gene rearrangements into BCL2, BCL6 or C-MYC chromosomal loci Vitolo et al., 1998 and references therein). Interestingly, the incidence of C-MYC gene rearrangements in tumors from HIV seropositive individuals is considerably higher than in those with no prior HIV exposure (Ladanyi et al., 1991) . Using molecular probes that detect 485% of C-MYC gene rearrangements in BL, translocations in fewer than 10% of non-HIVassociated DLBLs were detected. In contrast, cytogenetic studies revealed a much higher incidence of classical t(8;14)(q24;q32) translocation (Ladanyi, 1991) . Together, these studies indicate that C-MYC gene rearrangements in DLBL are`atypical' and may actually occur in a greater proportion of cases than is revealed by standard molecular analyses.
In addition to the above described translocations, Rao et al. (1998) have recently described ampli®cation of C-MYC and BCL2 in 15 and 11%, respectively of DLBLs from a panel of 96 cases. Although the levels of ampli®cation were generally quite modest (4 ± 10-fold), they tended to be associated with advanced stage disease. It will be important to verify the prognostic value of these observations in larger prospective studies.
Finally, as in the case of BLs and AIDS-related BLLs, DLBLs with C-MYC gene rearrangements have been reported to harbor somatic mutations in both C-MYC and TSP53 genes Farugia et al., 1994) .
Breast cancer
The ®rst report of C-MYC gene abnormalities in primary breast cancer was that of Escot et al. (1986) who detected low-moderate ampli®cation (2 ± 15-fold) in 32% of 121 tumors. With the exception of three cases, all tumors with ampli®ed C-MYC were invasive ductal carcinomas. Ten of 14 cases examined also expressed elevated levels of c-myc mRNA. These investigators also noted a correlation between C-MYC ampli®cation and patient age 450 year.
Con®rmation and extension of this original ®nding have been provided in numerous subsequent reports (Cline et al., 1987; Varley et al., 1987; Lidereau et al., 1988; Berns et al., 1992a,b; Pertschuk et al., 1993; Roux-Dosseto et al., 1992; Harada, 1994) . For example, Berns et al. (1992a) have observed that the frequency and extent of C-MYC ampli®cation in nearly 1000 primary tumors (17.1%; 3 ± 18-fold ampli®cation) was quite similar to that of HER2/neu (18.7%; 3 ± 43-fold ampli®cation). In addition, they observed C-MYC ampli®cation to be more prevalent in patients with progesterone receptor-negative tumors. In a subsequent prospective study of 282 patients with a 74 month medain follow-up, this same group (Berns et al., 1992b) did not ®nd any correlation with age but did observe C-MYC ampli®cation to be more common in larger tumors and to be strongly predictive of progressive disease, particularly in association with steroid receptor-positivity and lack of lymphatic involvement.
In the report of Pertschuk et al. (1993) , two groups of tumors, all obtained at the time of initial biopsy and prior to the start of treatment, were studied. The ®rst group of tumors was obtained from patients who had a 46.4 year mean disease-free survival (DFS) after initial surgery, whereas the second group was obtained from patients who had rapid disease recurrence or progression (mean DFS=1.4 year). Tumors from the latter group had nearly twice the level of C-MYC amplification (56 vs 30%) whereas HER2/neu ampli®cation was equivalent in both groups (19 and 20%). The somewhat higher overall incidence of C-MYC ampli®cation in comparison to other studies was likely due to lower cuto criteria. Other well established disease parameters were also independently predictive of outcome. In the most extreme example, women with negative lymph nodes, estrogen and progesterone receptor positivity, and unampli®ed C-MYC had a 0% recurrence rate whereas those with evidence of lymph node involvement, estrogen and progesterone receptor negativity, and ampli®ed C-MYC had a 93% likelihood of progression or recurrence.
In a somewhat similarly constructed study, RouxDosseto et al. (1992) grouped patients who initially had node-negative disease at the time of initial biopsy into those who experienced long-term DFS versus those whose tumors recurred. A signi®cantly higher incidence of C-MYC ampli®cation was observed in the latter group of patients. Multivariate analysis indicated that C-MYC ampli®cation served as an independent prognostic indicator of early relapse, more powerful than either estrogen receptor status or tumor size.
Finally, in a study of 457 primary breast cancers, Harada et al. (1994) found C-MYC ampli®cation in 28% of tumors. However, there was no signi®cant association with tumor stage or the presence of nodal disease.
A signi®cant problem with many of the above studies was that no correlations were made between C-MYC gene ampli®cation and expression at either the mRNA or protein level. Two studies which used dierent methods to quantitate c-myc protein in tumor samples concluded that oncoprotein levels could not be used to predict prognosis (Locker et al., 1989; Spandidos et al., 1989) . However, neither of these studies looked at levels of c-myc ampli®cation. More importantly, because Western blotting was not used in either case, these studies failed to prove that only authentic c-myc, and not cross-reactive proteins, was being detected.
An interesting albeit indirect way of assessing c-myc activity in primary breast tumors has recently been described by Mimori et al. (1998) who measured levels of ODC mRNA in 53 cases. The authors found a direct correlation between the levels of ODC transcripts and tumor size and an inverse correlation with prognosis. No attempt was made, however, to show a direct correlation between levels of c-myc mRNA or protein and ODC levels.
In summary, most studies pertaining to the role of cmyc in breast cancer have tended to indicate that a correlation exists between gene ampli®cation and disease progression or recurrence that ultimately in¯uences long term DFS. Virtually all of these studies, however, suer from the failure to correlate ampli®cation with speci®c expression. Clearly, additional studies are needed to corroborate these potentially important ®ndings. Ideally these should be designed along the same lines as those used to establish the relationship between HER2/neu overexpression and prognosis (Slamon et al., 1989 , and references therein). They should include methods designed to provide unequivocal evidence of C-MYC ampli®cation and expression using Southern and Northern blotting (not slot blotting) or highly quantitative PCR-based procedures. Protein expression studies should rely on Western blotting procedures of proven ability to detect authentic and appropriately sized c-myc. Measurements of target gene products such as ODC have the potential for adding considerable information regarding c-myc protein function in vivo. However, it will ®rst be necessary to establish that such assays truly re¯ect c-myc protein levels.
A ®nal interesting observation has recently been made by Wang et al. (1998b) who have detected both in vitro and in vivo associations between c-myc protein and the product of the BRCA1 tumor suppressor. BRCA1 overexpression was also shown to suppress cmyc-mediated transcriptional activation and to reverse the transformed phenotype of c-myc+ras transfected primary ®broblasts. Because BRCA1 has recently been implicated in the repair of DNA damage (Scully et al., 1997) , it is tempting to suggest that one of its other roles is to attenuate the ability of c-myc to participate in the G0?S transition until genomic integrity is restored. It will be important in future work to determine whether naturally occurring BRCA1 mutant proteins have lost the ability to suppress the c-myc activities described above.
Prostate cancer
Convincing evidence for C-MYC ampli®cation in prostate cancer has not been forthcoming until quite recently. Jenkins et al. (1997) used FISH and immunocytochemistry to evaluate the status and expression of C-MYC in 48 matched samples of highgrade prostatic intraepithelial neoplasia (PIN) (48 foci), localized prostatic carcinoma (71 foci), and metastases (23 foci). Large increases in C-MYC copy number relative to the chromosome 8 centromere, and concurrent increases in c-myc immunoreactivity, were observed in 0, 8 and 21% of foci of PIN, carcinoma, and metastases, respectively. Signi®cant intratumoral molecular heterogenity was also observed, suggesting the independent and simultaneous evolution of tumor cells within an otherwise histologically uniform focus. A more recent report using both FISH and comparative genomic hybridization (CGH) has provided con®rmation for some of these ®ndings by demonstrating 4threefold ampli®cation of C-MYC in 29% of prostatic carcinomas (Nupponen et al., 1998) . However, this study did not determine whether C-MYC ampli®cation was associated with tumor progression.
Members of the mad bHLH-ZIP family are antagonists of myc oncoprotein function and are thus potential tumor suppressors (reviewed in Henriksson and Luscher, 1996) . MXI1, one of the members of this family, has been mapped to 10q25, a region that is commonly deleted in prostate cancer (Shapiro et al., 1994) . We have provided FISH and molecular evidence for deletion and inactivation of MXI1 in approximately one-half of primary carcinomas of the prostate (Eagle et al., 1995; . It is noteworthy that, in keeping with the concept of extreme tumor heterogenity prostate cancer (Jenkins et al., 1997; Prochownik et al., 1998 and references therein), MXI1 mutations were detected in only a minority of PCR-ampli®ed alleles. In fact, the detection of these mutations required the cloning of PCR products obtained from tumor DNA and the sequencing of individual clones. The failure of three other groups to detect MXI1 mutations may well be due to the fact that DNA analyses were performed on the uncloned PCR-ampli®ed population of molecules (Gray et al., 1995; Kawamata et al., 1996; Kuczyk et al., 1998) .
Recently, the dual-speci®city phosphatase PTEN/ MMAC1 has been proposed as a candidate tumor suppressor gene in prostate cancer Steck et al., 1997) . The PTEN/MMAC1 gene maps to 10q23.3 and may be deleted and/or mutated in primary glioblastomas, in breast, kidney, and prostate cancer cell lines and in prostate cancer xenografts Steck et al., 1997; Vlietstra et al., 1998; Whang et al., 1998) . Studies with primary prostate tumor material, however, have yielded con¯icting results. Wang et al. (1998a) have reported homozygous PTEN/MMAC1 deletion in eight of 60 cases of primary prostate cancer but there were no detectable point mutations in any tumors exhibiting loss of heterozygosity (LOH) at 10q23. Suzuki et al. (1998) , in a study of advanced disease, were able to demonstrate either homozygous deletion or point mutations in metastatic lesions from 12 of 19 patients. In contrast, at least three studies, despite documenting 10q23 LOH, have either not con®rmed the presence of PTEN/MMAC1 point mutations or have observed them in only a very small fraction of tumors (Feilotter et al., 1998; Orikasa et al., 1998; Pesche et al., 1998) . The clinical picture of individuals with Cowden disease, a familial cancer syndrome resulting from the inheritance of a mutant PTEN/ MMAC1 gene further contributes to the confusion. Though predisposed to the development of breast, thyroid, and skin cancers, as well as meningiomas, these patients do not develop prostate cancer at a particularly high rate (Liaw, 1997 and references therein) .
In summary, conclusive evidence for a role for either MXI1 or PTEN/MMAC1 in prostate cancer remains elusive. Perhaps the most conservative conclusion regarding the role for these genes in prostate cancer is that somatic inactivation of both alleles of either gene is a relatively late stage event that contributes more to evolution of the tumor than to its actual initiation (Eagle et al., 1995; Prochownik et al., 1998) . It is intriguing that targeted inactivation of either gene in mice is associated with prostatic dysplasia (Schreiber-Agus et al., 1998; Di Cristofano et al., 1998) . et al. (1985) were the ®rst to show 5 ± 40-fold overexpression of c-myc mRNA in primary human colon adenocarcinoma as compared to adjacent normal mucosa. Numerous subsequent reports have provided con®rmation of this ®nding at both the mRNA and protein level in both cell lines and primary tumors (Erisman et al., 1988; Finley et al., 1989; Rochlitz et al., 1996; Stewart et al., 1986; Yang et al., 1996) . Although the original report by Erisman et al. (1985) reported that the C-MYC gene was not ampli®ed in tumors, several subsequent studies have provided evidence for low-level ampli®cation (2 ± 5-fold) in about one-third of tumors (Finley et al., 1989; Rochlitz et al., 1996; Augenlicht et al., 1997; Masramon et al., 1998) . However, this does not explain the disproportionate increase in c-myc expression in the vast majority of tumors.
Gastrointestinal cancer
Erisman
The clinical signi®cance of c-myc overexpression has been investigated in several studies. Interestingly, and in contradistinction to virtually all other disease states associated with MYC gene overexpression, Smith and Goh et al. (1996) and Augenlicht et al. (1997) both observed that C-MYC ampli®cation or overexpression were associated with reduced mortality. In the former study, the survival advantage of c-myc overexpression was lost in tumors which also expressed mutant p53 proteins. It was postulated that tumors which overexpress c-myc might be more predisposed toward apoptosis.
Nearly a decade ago, Erisman et al. (1989) made the intriguing observation that colorectal tumors which express high levels of c-myc are frequently associated with LOH for markers on chromosome 5q, a region which, at that time, was known to be the locus for the familial adenomatous polyposis (APC) gene. Subsequent experiments by the same group demonstrated that microcell-mediated transfer of chromosome 5 into high c-myc expressing colon cancer cell lines resulted in a dramatic reduction in c-myc expression and tumorigenicity in nude mice (Rodriguez-Alfageme et al., 1992) .
Recent observations have revealed the potential molecular link between c-myc and APC commentary by Penisi, 1998) . The APC gene product is normally localized in the cytoplasm where it sequesters b-catenin, promotes its degradation, and prevents it entry into the nucleus. Colon cancer-associated APC mutations are unable to bind b-catenin with the result that b-catenin enters the nucleus . In some tumors with otherwise normal APC, b-catenin itself is mutated, is unable to bind APC, and enters the nucleus . In either case, intranuclear b-catenin serves as a co-activator for the Tcf-4 transcription factor, one target of which is C-MYC . The conditional expression of wild-type APC in a APC-colon cancer cell line resulted in the rapid down-regulation of c-myc mRNA and protein and in the eventual apoptotic demise of the cell. Furthermore, the c-myc promoter was repressed by wild-type APC overexpression, and was activated by mutant bcatenin overexpression. It was shown that the C-MYC promoter contains two consensus Tcf-4 binding sites, mutation of which render it insensitive to both APC and b-catenin-mediated regulation .
A potential role for the APC-b-catenin-c-myc pathway in the pathogenesis of other gastrointestinal cancers has recently been suggested by the ®nding of bcatenin mutations in 19 ± 26% of hepatocellular cancers (de La Coste et al., 1998; Miyoshi et al., 1998) . In the former study, intranuclear accumulation of mutant bcatenin was demonstrated. It will clearly be important to evaluate these mutants to determine if they have acquired an enhanced ability to activate the C-MYC promoter in association with Tcf-4.
Finally, several workers have reported C-MYC ampli®cation of up to 30-fold in gastric cancer (Shibuya et al., 1985; Hajdu et al., 1997; Suzuki et al., 1997; Hara et al., 1998) . In one study (Hajdu et al., 1997) there was a strong association between ampli®cation and the presence of metastatic disease. In light of the known association between other gastrointestinal cancers and the APC-b-catenin-c-myc pathway discussed above, it will be of interest to investigate this pathway in gastric cancer.
Melanoma
Recent studies have suggested that c-myc overexpression correlates with shortened overall survival in scalp and subungual melanomas (Grover et al., 1997a; Chana et al., 1998a) . c-myc may also be expressed at higher levels in metastatic lesions than in the primary tumor (Grover et al., 1996) where its level has been suggested to be a more powerful prognostic marker than any other clinicopathologic measurement, including the presence of nodal disease (Grover et al., 1997b) . In contrast, one report suggests that high level c-myc expression in uveal melanoma is associated with improved outcome (Chana et al., 1998b) . Finally, the recent ®nding of b-catenin mutations in some melanoma cell lines (Rubinfeld et al., 1997) mandates that they be corroborated in primary tumors and compared functionally to those mutants associated with colorectal cancers.
Multiple myeloma
Although Ig translocations are frequent in both murine plasmacytomas and human multiple myelomas (MM), they rarely, if ever, in the latter case involve the C-MYC locus (reviewed in Bergsagel et al., 1997) . Nonetheless, in a 180 case series using immunohistochemical staining, the level of c-myc expression was reported to correlate with the grade of malignancy and the total tumor burden (Skopelitou et al., 1993) . More recently, observations by two groups have suggested a possible new means by which c-myc may be deregulated in this disease. Using six cell lines with polymorphic C-MYC alleles, showed a selective expression of one of the alleles. Willis et al. (1997) showed that in some MM cell lines, there is an increased amount of c-myc mRNA and a 4threefold increase in its association with polyribosomes. In all cases, the mRNAs have suered mutations in their 5'-untranslated region which appears to account for their altered association with polysomes. It is possible that the allelic extinction of c-myc expression observed by Kuehl et al. (1997) may represent a feedback phenomenon by a c-myc protein originating from a selectively expressed mutant c-myc mRNA of the type described by Willis et al. (1997) . It will be important to con®rm these observations in a larger number of primary patient samples.
Myeloid leukemia
Double minute chromosomes (DMs) are seen infrequently in acute and chronic nonlymphocytic leukemias. However a number of reports, all consisting of individual or small numbers of patients, have reported C-MYC ampli®cation in association with DMs Asker et al., 1988; Fugazza et al., 1997; Tanaka et al., 1993; Slovak et al., 1994; Karasawa et al., 1996; Mohamed et al., 1996; Reddy and Sulcova, 1997; Jennings and Mills, 1998) . Because of the limited sizes of each study and institutional variability in management, the prognostic value of these ®ndings remains uncertain.
N-myc and human disease
Neuroblastoma (NBL)
The original characterization of N-myc as a c-mycrelated gene (Stanton et al., 1986) was soon followed by reports of its ampli®cation in approximately onethird of cases of NBL, as well as by the observation that the degree of ampli®cation correlated inversely with prognosis (Brodeur et al., 1984 (Brodeur et al., , 1985 . These original ®ndings have generally been con®rmed in subsequent studies (Combaret et al., 1996; Rubie et al., 1997; Tsuda et al., 1997) . Overall, N-MYC ampli®cation remains the most widely accepted predictive parameter of long-term, disease-free survival.
Because c-myc and N-myc share many properties, it seems likely that the mechanism by which they transform their respective target tissues will be quite similar, if not identical. For example, it has recently been shown (Lutz et al., 1996) that the conditional upregulation of N-myc in a non-N-MYC-ampli®ed NBL cell line can drive quiescent cells into an abortive S phase and induce the expression of two c-myc target genes, (a)-prothymosin and ODC (Eilers et al., 1991; Bello-Fernandez et al., 1993) . Using a single NBL cell line with diering amounts of N-myc expression, a direct correlation has been shown between N-myc levels and growth rate, motility, and proteolytic activity. In contrast, an inverse correlation with tumor cell attachment was seen (Goodman et al., 1997) .
Surprisingly, direct evidence for the involvement of N-myc in NBL had been lacking until quite recently when Weiss et al. (1997) showed that the neuroectodermal-speci®c expression of N-myc leads to the development of a NBL-like disease in transgenic mice. Crossbreeding with animals lacking either the NF-1 or pRb tumor suppressors augmented tumorigenesis and CGH studies on tumor cells showed gains and losses of regions syntenic to those altered in human NBL.
In addition to providing a model that seems to mimic human NBL quite faithfully, the above study also underscores the role of genes which modify tumor behavior. Indeed, there is considerable evidence to suggest a role for such factors in human NBL. Some investigators have shown a relationship between Bcl-2 overexpression and the degree of N-MYC amplification and unfavorable histology (Castle et al., 1993; Mejia et al., 1998) , although another study found no such correlation (Ikegaki et al., 1998) . Somewhat better agreement has been obtained with respect to the role of the members of the Trk family of neurotrophin receptors in the clinical behavior of NBLs. Expression of TrkA and TrkC have been shown in several studies to be associated with favorable outcome whereas expression of TrkB has been associated with N-MYC ampli®cation and poor outcome (Tanaka et al., 1995 Yamashiro et al., 1996; Brodeur et al., 1997; Combaret et al., 1997) . The increasing evidence in support of a role for these receptors in NBL survival and dierentiation suggests rational therapeutic approaches based on the use of appropriate ligands or their antagonists.
The role for tumor suppressor genes in NBL has generated great interest. In view of the putative role for APC in the expression of c-myc in colorectal cancers, the observation by Meltzer et al. (1996) showing allelic imbalance of the APC locus in over one-third of NBLs deserves further investigation. The ®nding that such imbalance was seen only in tumors lacking N-MYC ampli®cation raises the possibility that non-ampli®ed deregulation of either N-MYC (or C-MYC) represent an alternate pathway in the initiation or progression of NBL. It will be important to document the actual presence of APC and b-catenin mutations in NBL, and to correlate these with N-MYC ampli®cation (or lack thereof) as well as the unampli®ed overexpression of both Nmyc and c-myc.
One or more tumor suppressor loci on chromosome 1p have also been documented in NBL. Among the cell lines studied, those without N-MYC amplification tended to harbor small deletions involving 1p36.23-33 whereas those with ampli®cation had larger deletions, often extending to the telomere (Cheng et al., 1995; Caron et al., 1995) . One parsimonious interpretation of these ®ndings is that the region contained within the smaller deletion encodes a suppressor whose function is lost very early and is important for tumor initiation. In turn, the region contained within the larger deletion may be necessary for maintaining N-MYC in single copy form. A recent report has suggested that patients with 1p loss and non N-MYC-ampli®ed tumors are nonetheless at high risk for tumor progression (Caron et al., 1996 and references therein) . Although neither the sizes of the 1p deletions nor the extent of N-MYC ampli®cations in these patients was described, it is tempting to speculate that these patients either had the larger 1p deletion at the time of diagnosis or developed it in association with progression and concurrent N-MYC amplification. Norris et al. (1996) have observed that overexpression of the gene encoding the multidrugresistance-associated protein (MRP) in untreated, advanced stage NBL with N-MYC ampli®cation correlated with reduced event-free and overall survival. Although this may potentially explain the inherent drug-resistance of NBL, it is noteworthy that the dierence in MRP expression between favorable and unfavorable NBLs, although significant, were 5twofold. This contrasts to the 100 ± 200-fold degree of overexpression observed in the cell line from which the MRP cDNA was originally isolated (Cole et al., 1992) . It will be of interest to determine whether engineering NBL cell lines to express such low levels of MRP recapitulates the drug resistance phenotype seen in naturally-occurring tumors. One would also expect to observe an increase in MRP expression in recurrent tumors. Clearly, further investigation is necessary to determine whether the MRP gene is an actual target of the N-myc protein.
Other tumors
Overexpression of N-MYC has been described in a signi®cant proportion of small cell lung cancers as well as in sporadic or small numbers of cases of medullary thyroid carcinoma, retinoblastoma, alvelolar rhabdomyosarcoma, and breast cancer (Boultwood et al., 1988; Driman et al., 1994; Roncalli et al., 1994; Mizukami et al., 1995; Doz et al., 1996) . It will be important to con®rm and extend these observations in much larger series and to determine what role, if any N-MYC ampli®cation and overexpression plays in tumor behavior.
L-myc and human disease
Small cell lung cancer (SCLC)
Because SCLCs may show ampli®cation and overexpression of all three MYC oncogenes, we have chosen to discuss them together in this section. Nau et al. (1985) were the ®rst to report the cloning of L-MYC and its ampli®cation in SCLC. Subsequently, numerous con®rmatory reports of L-MYC ampli®cation and overexpression in SCLC cell lines, primary tumors, and tumor xenografts have appeared (Johnson et al., 1987 (Johnson et al., , 1992 Gu et al., 1988; Takahashi et al., 1989; Noguchi et al., 1990; Gazzeri et al., 1990; Makela et al., 1992; Rygaard et al., 1993) . In general, the incidence of L-MYC ampli®cation and/or overexpression in primary SCLC tumors have been reported to be in the range of 5 ± 10% (Johnson et al., 1987 (Johnson et al., , 1992 Takahashi et al., 1989; Noguchi et al., 1990 ). This range is higher (perhaps up to 50%) in SCLC cell lines, xenografts, and in cell lines derived from treated versus untreated patients (Johnson et al., 1987; Gu et al., 1988; Gazzeri et al., 1990; Rygaard et al., 1993) , although this has not invariably been the case (Johnson et al., 1992) . In most of the above studies in which it was investigated, up to 40-fold ampli®cation and overexpression relative to control tissues or cell lines were observed. Although several reports have suggested an association between L-MYC ampli®cation and disease stage, progression, and overall survival, a summary of 15 such studies concluded that this relationship was tenuous at best (Johnson et al., 1992) .
In addition to the infrequent L-MYC ampli®cation in SCLC discussed above, both C-MYC and N-MYC ampli®cation and overexpression have also been observed (Little et al., 1983; Saksela et al., 1984; Nau et al., 1986; Funa et al., 1987; Johnson et al., 1987 Johnson et al., , 1992 Gu et al., 1988; Takahashi et al., 1989; Noguchi et al., 1990; Makela et al., 1992; Rygaard et al., 1993) . The frequency of ampli®cation/overexpression for either gene has generally ranged from 2 ± 30% of all tumors, xenografts or cell lines and the extent of ampli®cation has ranged from 5 ± 4100-fold. Several studies have reported the co-ampli®cation of (almost always) two MYC family members (Gu et al., 1988; Noguchi et al., 1990; Johnson et al., 1992; Rygaard et al., 1993) but no consistent clinical correlations to suggest an impact on prognosis have been made.
In addition to MYC family member ampli®cation and overexpression, SCLC is frequently associated with a host of other genetic abnormalities including an 80% incidence of p53 mutations and a 490% incidence of pRb mutations (reviewed in Salgia and Skarin, 1998) . Precisely how these abnormalities aect the behavior of MYC ampli®ed tumors has yet to be determined.
An EcoRI restriction fragment length polymorphism in the L-MYC gene can be used to distinguish parental alleles (Nau et al., 1985) . Scattered reports have suggested that individuals bearing the`short' (S) allele either have an increased incidence of certain tumors and/or that such tumors manifest a more aggressive behavior. The associated neoplasms include soft-tissue sarcomas (Kato et al., 1990) , oral cancers (Saranath et al., 1990) , colorectal cancers (Young et al., 1994) , nonHodgkin's lymphoma (Crossen et al., 1994) , breast cancer (Champeme et al., 1992) , and non-SCLC lung cancer (Kawashima et al., 1988) . In contrast, at least one report has suggested that the`SS' genotype protects against hepatocellular cancer (Taylor et al., 1993) . A major problem with all of the above studies is the lack of data pointing to any qualitative or quantitative dierences in expression of the two alleles or that they serve as markers for functionally dierent L-myc protein isoforms. Another problem is the lack of data showing expression of L-myc mRNA or protein in any of the tumors studied. The predictive value of L-MYC allelic dierences in lung cancer has been called into question by several subsequent studies (Tamai et al., 1990; Tefre et al., 1990; Weston et al., 1994) .
Concluding remarks
The evidence presented in this review strongly supports a critical role for the MYC oncogene family in the pathogenesis of diverse human cancers. Data from both the basic science and clinical literature has been used to support the argument that the c-myc, N-myc, and L-myc oncoproteins share many related-functions while at the same time retaining other, unique ones. It is likely that these latter properties, together with various tissue-speci®c factors, account for the unique spectra of diseases associated with each MYC gene.
Our current level of understanding of the involvement of the three MYC genes in the pathogenesis of cancer is quite variable. For example, the roles of C-MYC in Burkitt's lymphoma and N-MYC in neuroblastoma have been areas of intensive investigation and have yielded some of the strongest evidence to date for causative links. In other cases, the association between MYC gene deregulation, expression at the protein level, and disease initiation or progression is much more controversial. At the same time, the list of neoplasms associated with MYC gene deregulation has continued to expand. Investigation of the role of MYC oncogenes in human disease will likely continue to be an important area of scienti®c research for the foreseeable future. However, the challenge will be to apply techniques and to structure clinical studies which permit us to establish a direct role for these genes in disease causation. It should be expected that improved understanding of the roles these genes play in cancer, as well as in normal cellular processes with which they are so intimately associated, will lead to novel and highly speci®c therapeutic approaches.
